Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials

By Haiying Lu, Qiaodan Zhou, Jun He, Zhongliang Jiang, Cheng Peng, Rongsheng Tong, Jianyou Shi. Signal Transduction and Targeted Therapy, 2020

718 citations recorded by the source corpus.

Protein–protein interactions (PPIs) have pivotal roles in life processes. The studies showed that aberrant PPIs are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. Therefore, targeting PPIs is a direction in treating diseases and an essential strategy for the development of new drugs. In the past few decades, the modulation of PPIs has been recognized as one of the most challenging drug discovery tasks. In recent years, some PPIs modulators have entered clinical studies, some of which been approved for marketing, indicating that the modulators targeting PPIs have broad prospects. Here, we summarize the recent advances in PPIs modulators, including small molecules, peptides, and antibodies, hoping to provide some guidance to the design of novel drugs targeting PPIs in the future.

Subfields: Molecular Biology

View Paper: https://www.semanticscholar.org/paper/59f22d52d6ed1a11a6d63d8691715ce2daf6d3a3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. J. Sáez-Rodríguez
2. R. Argelaguet

Citations in the corpus

• Gene regulatory network inference in the era of single-cell multi-omics (2023, methodology): “Other approaches include using protein–protein interaction assays 118 or checking databases of previously annotated interactions 119 .”